Weight loss in breast cancer patient management

被引:459
作者
Chlebowski, RT
Aiello, E
McTiernan, A
机构
[1] Univ Calif Los Angeles, Res & Educ Inst, Torrance, CA 90502 USA
[2] Fred Hutchinson Canc Res Ctr, Seattle, WA USA
关键词
D O I
10.1200/JCO.20.4.1128
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To systematically review and summarize evidence relevant to obesity and breast cancer clinical outcome, potential hormonal mediating mechanisms, and the current status of weight loss interventions for chronic disease management. Methods: A comprehensive, formal literature review was conducted to identify 5,687 citations with key information from 159 references summarized in text and tables. This process included a search for all breast cancer studies exploring associations among survival or recurrence and obesity at diagnosis or weight gain after diagnosis using prospective criteria. Results: On the basis of observational studies, women with breast cancer who are overweight or gain weight after diagnosis are found to be at greater risk for breast cancer recurrence and death compared with lighter women. Obesity is also associated with hormonal profiles likely to stimulate breast cancer growth. Recently, use of weight loss algorithms proven successful in other clinical settings that incorporate dietary therapy, physical activity, and ongoing behavior therapy have been endorsed by the National Institutes of Health and other health agencies. Conclusion: Although definitive weight loss intervention trials in breast cancer patients remain to be conducted, the current evidence relating increased body weight to adverse breast cancer outcome and the documented favorable effects of weight loss on clinical outcome in other comorbid conditions support consideration of programs for weight loss in breast cancer patients. Recommendations for the clinical care of overweight or obese breast cancer patients are offered. (C) 2002 by American Society of Clinical Oncology.
引用
收藏
页码:1128 / 1143
页数:16
相关论文
共 176 条
  • [1] Anderson G, 1998, CONTROL CLIN TRIALS, V19, P61
  • [2] [Anonymous], 2000, P AM SOC CLIN ONCOL
  • [3] [Anonymous], P ASCO
  • [4] Multiple endocrine abnormalities of the growth hormone and insulin-like growth factor axis in prepubertal children with exogenous obesity: Effect of short- and long-term weight reduction
    Argente, J
    Caballo, N
    Barrios, V
    Pozo, J
    Munoz, MT
    Chowen, JA
    Hernandez, M
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1997, 82 (07) : 2076 - 2083
  • [5] Changes in body composition during breast cancer chemotherapy with the CMF-regimen
    Aslani, A
    Smith, RC
    Allen, BJ
    Pavlakis, N
    Levi, JA
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 1999, 57 (03) : 285 - 290
  • [6] BARBER GR, 1995, ARCH SURG-CHICAGO, V130, P1042
  • [7] A pill for all by the year 2000?
    Barrett-Connor, E
    [J]. PREVENTIVE MEDICINE, 1999, 28 (06) : 600 - 607
  • [8] OBESITY AS AN ADVERSE PROGNOSTIC FACTOR FOR PATIENTS RECEIVING ADJUVANT CHEMOTHERAPY FOR BREAST-CANCER
    BASTARRACHEA, J
    HORTOBAGYI, GN
    SMITH, TL
    KAU, SWC
    BUZDAR, AU
    [J]. ANNALS OF INTERNAL MEDICINE, 1994, 120 (01) : 18 - 25
  • [9] Tamoxifen therapy for breast cancer and endometrial cancer risk
    Bernstein, L
    Deapen, D
    Cerhan, JR
    Schwartz, SM
    Liff, J
    McGann-Maloney, E
    Perlman, JA
    Ford, L
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1999, 91 (19) : 1654 - 1662
  • [10] Berrino F, 2001, CANCER EPIDEM BIOMAR, V10, P25